RhumbLine Advisers’s Co-Diagnostics CODX Stock Holding History

RhumbLine Advisers’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-32	Closed	-$1.22K	–	4227
2024 Q2	$1.22K	Hold	32	–	–	﹤0.01%	4225
2024 Q1	$1.09K	Hold	32	–	–	﹤0.01%	4140
2023 Q4	$1.29K	Hold	32	–	–	﹤0.01%	4131
2023 Q3	$1.03K	Hold	32	–	–	﹤0.01%	4179
2023 Q2	$1.08K	Buy	+32	New	+$1.22K	﹤0.01%	4281
2021 Q2	–	Sell	-1,047	Closed	-$300K	–	3013
2021 Q1	$300K	Sell	1,047 -69	-6%	-$27.5K	﹤0.01%	2696
2020 Q4	$311K	Buy	1,116 +43	+4%	+$15.9K	﹤0.01%	2646
2020 Q3	$437K	Sell	1,073 -167	-13%	-$85.8K	﹤0.01%	2347
2020 Q2	$720K	Buy	+1,240	New	+$566K	﹤0.01%	2183

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KOC

Koss-Olinger Consulting Gainesville, Florida $1.19B AUM 15.91% 1-Year Est. Return

RhumbLine Advisers's CODX Position: Q3 2024 in Review

RhumbLine Advisers sold out of Co-Diagnostics (CODX) in Q3 2024, closing a stake of 32 shares — an estimated $1.22K sold.

RhumbLine Advisers first reported a position in CODX in Q2 2020 and held it in 9 quarters. The position peaked at $720K in Q2 2020. 36 funds tracked by Wall St. Rank hold CODX as of Q3 2024.

RhumbLine Advisers reported no remaining Co-Diagnostics position as of Q3 2024 after selling out during the quarter.
RhumbLine Advisers sold 32 Co-Diagnostics shares in Q3 2024, an estimated $1.22K.
RhumbLine Advisers first reported a position in Co-Diagnostics in Q2 2020 and held it in 9 quarters.
RhumbLine Advisers's Co-Diagnostics position peaked at $720K in Q2 2020.
36 funds tracked by Wall St. Rank held Co-Diagnostics as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.